New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
10:32 EDTDEPO, ACTDepomed higher after favorable ruling in Gralise case
Shares of Depomed (DEPO) moved higher after a judge in New Jersey ruled in favor of the company in the company's Gralise case against Actavis (ACT).
News For DEPO;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 23, 2015
16:14 EDTACTPershing Square liquidates stake in Allergan
Subscribe for More Information
07:36 EDTACTPfizer should rise 'significantly' over next two years, says Jefferies
Jefferies analyst Jeffrey Holford told investors this morning that he expects shares of Pfizer (PFE) to appreciate "significantly" over the next two years. A survey of U.S. oncologists indicated the company's Ibrance drug will be used in 50% of first line hormonal therapy within one year, with off-label use in all lines of therapy including adjuvant, Holford noted. He thinks peak sales of the drug could top $13B, which is well above consensus. In addition, the analyst views Pfizer's Global Established Pharmaceutical business as being underappreciated by the market. Potential value creating options for the pharmaceutical giant include spinning off its GEP unit by 2017 and accretive acquisitions, with possible takeover targets being Shire (SHPG), Actavis (ACT), AstraZeneca (AZN) and GlaxoSmithKline (GSK), in the eyes of Holford. He added the stock to the firm's Franchise Picks list, which encompasses its best ideas. He also raised his price target for Pfizer to $45 from $42. The stock closed Friday up 10c to $34.25.
07:17 EDTACTAmerican Academy of Dermatology to hold annual meeting
73rd Annual Meeting of AAD is being held in San Francisco on March 20-24.
March 20, 2015
14:46 EDTACTNoven files patent infringement lawsuit against Actavis
Subscribe for More Information
07:41 EDTACTAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 19, 2015
10:02 EDTDEPOOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:22 EDTDEPODepomed downgraded to Neutral at Janney Capital
Subscribe for More Information
08:16 EDTDEPODepomed downgraded to Neutral from Buy at Janney Capital
Subscribe for More Information
March 18, 2015
08:50 EDTACTActavis price target raised to $373 from $286 at BMO Capital
Subscribe for More Information
March 17, 2015
09:19 EDTACTActavis reinstated with a Conviction Buy at Goldman
Subscribe for More Information
09:13 EDTACTActavis says Allergan CEO not joining combined company board
Subscribe for More Information
08:59 EDTACTActavis sees combined annual pro forma revenues of over $23B in 2015
Subscribe for More Information
08:58 EDTACTActavis sees double digit accretion to adjusted EPS within first 12 months
08:58 EDTACTActavis says will 'immediately begin implementing' integration plans
Subscribe for More Information
08:57 EDTACTActavis completes acquisition of Allergan
Actavis plc (ACT) announced that it has completed the acquisition of Allergan (AGN) in a cash and equity transaction valued at approximately $70.5B. The combination creates one of the world’s top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23B anticipated in 2015. Actavis continues to expect the transaction to generate double-digit accretion to non-GAAP earnings within the first 12 months, including approximately $1.8B in operating and financial synergies to be realized within one year following the close. These synergies exclude any additional revenue or manufacturing synergies, and are in addition to the $475M of annual savings previously announced by Allergan in connection with Project Endurance. Actavis further expects to generate strong operating cash flow in excess of $8B in 2016, which would enable the company to rapidly de-lever the balance sheet.
08:56 EDTACTActavis completes Allergan acquisition valued at $70.5B
Subscribe for More Information
08:35 EDTDEPODepomed announces expiration of waiting period to acquire rights of NUCYNTA
Depomed announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired with respect to Depomed's pending acquisition of U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals. The termination of the waiting period under the HSR Act satisfies one of the conditions to the closing of the pending acquisition, which remains subject to completion of Depomed's previously announced financing and other customary closing conditions.
March 16, 2015
18:38 EDTACTAmerican Airlines to replace Allergan in S&P 500 as of 3/20 close
Subscribe for More Information
16:10 EDTACTActavis receives FDA approval for VIIBRYD 20mg once daily
Subscribe for More Information
10:22 EDTACTEuropean Commission clears Actavis' pending acquisition of Allergan
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use